Pleural Disease This review discusses the substantial advances that have been made in our
understanding of pleural biology and related pathophysiology, as well as in the …

Cancer immunotherapy has gained momentum for treating malignant tumors over the past
decade. Checkpoint blockade and chimeric antigen receptor cell therapy (CAR-T) have …

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with
locally advanced or metastatic lung cancer requires an accurate and affordable tool. Tumor …

Background: This Guideline, a collaborative effort from the American Thoracic Society,
Society of Thoracic Surgeons, and Society of Thoracic Radiology, aims to provide evidence …

Immune checkpoint blockade (ICB) has been a remarkable clinical advance for cancer;
however, the majority of patients do not respond to ICB therapy. We show that metastatic …

Cell membrane–derived microparticles (MPs), the critical mediators of intercellular
communication, have gained much interest for use as natural drug delivery systems. Here …

Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a
common symptom and accompanying manifestation of metastatic disease. It affects up to …

Background Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in
patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) …

Purpose Most malignant effusion is secondary to metastases to the pleura or peritoneum
and portend poor oncological outcomes. Malignant effusion has different tumor …

Sensitive early detection, along with effective treatments and solid postoperative monitoring
remain the grand challenges in fighting against human diseases, especially cancer.(1) In …